Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs may leads to higher adverse event: gastrointestinal disorders at 1‐month (with actual compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Ocular surface staining · people with dry eyea
1 finding from 1 review
Aqueous tear production · people with dry eyea
Combined oral omega‐3 and omega‐6 PUFAs showed no clear difference in schirmer test (aqueous tear production, measured in mm/5 min, with… compared with placebo (moderate certainty).
1 finding from 1 review